Jeremy Cetnar

2.8k total citations · 1 hit paper
42 papers, 1.4k citations indexed

About

Jeremy Cetnar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jeremy Cetnar has authored 42 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Jeremy Cetnar's work include Prostate Cancer Treatment and Research (11 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jeremy Cetnar is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Jeremy Cetnar collaborates with scholars based in United States and Switzerland. Jeremy Cetnar's co-authors include Joshi J. Alumkal, Matthew Taylor, Adam S. Kittai, Tomasz M. Beer, Hossein Borghaei, Shirish M. Gadgeel, Bogdana Balas, Bo H. Chao, Alberto Chiappori and Mark A. Socinski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Jeremy Cetnar

41 papers receiving 1.4k citations

Hit Papers

Alectinib in ALK-positive, crizotinib-resistant, non-smal... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
    2015 462 citations Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology profile →

Peers

Jeremy Cetnar
Ramon Andrade de Mello Portugal
Bo H. Chao United States
Jiuda Zhao China
Luisa Carbognin Italy
Angela Listì Italy
Luciano Burattini Italy
Carmen Belli Italy
Erzsébet Juhász Hungary
Chiara Lazzari Italy
Tindara Franchina Italy
Ramon Andrade de Mello Portugal
Jeremy Cetnar
Citations per year, relative to Jeremy Cetnar Jeremy Cetnar (= 1×) peers Ramon Andrade de Mello

Countries citing papers authored by Jeremy Cetnar

Since Specialization
Citations

This map shows the geographic impact of Jeremy Cetnar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Cetnar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Cetnar more than expected).

Fields of papers citing papers by Jeremy Cetnar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Cetnar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Cetnar. The network helps show where Jeremy Cetnar may publish in the future.

Co-authorship network of co-authors of Jeremy Cetnar

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Cetnar. A scholar is included among the top collaborators of Jeremy Cetnar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Cetnar. Jeremy Cetnar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2024). Abstract CT262: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11). Cancer Research. 84(7_Supplement). CT262–CT262.
3.
4.
Tsao, Anne S., Jeremy Cetnar, Boris Sepesi, et al.. (2021). OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma. Journal of Thoracic Oncology. 16(10). S870–S870. 7 indexed citations
5.
Gill, Jennifer, Jeremy Cetnar, & Vinay Prasad. (2020). A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. Trends in cancer. 6(9). 736–738. 3 indexed citations
6.
Camidge, D. Ross, Shirish M. Gadgeel, Leena Gandhi, et al.. (2017). MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S378–S378. 10 indexed citations
7.
Harrison, Michael R., Peter H. O’Donnell, Ajjai Alva, et al.. (2017). Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC). Annals of Oncology. 28. v303–v304. 2 indexed citations
8.
Danila, Daniel C., Timothy M. Kuzel, Jeremy Cetnar, et al.. (2016). A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). e16507–e16507. 2 indexed citations
9.
Graff, Julie N., Joshi J. Alumkal, Charles G. Drake, et al.. (2016). Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 7(33). 52810–52817. 262 indexed citations
10.
Aisner, Dara L., Lynette M. Sholl, Lynne D. Berry, et al.. (2016). Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.. Journal of Clinical Oncology. 34(15_suppl). 11510–11510. 16 indexed citations
11.
Shaw, Alice T., Leena Gandhi, Shirish M. Gadgeel, et al.. (2015). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. The Lancet Oncology. 17(2). 234–242. 462 indexed citations breakdown →
12.
Potretzke, Aaron M., Luke Hillman, Kelvin Wong, et al.. (2014). NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urologic Oncology Seminars and Original Investigations. 32(5). 631–636. 40 indexed citations
13.
Cetnar, Jeremy & Tomasz M. Beer. (2014). Personalizing prostate cancer therapy: the way forward. Drug Discovery Today. 19(9). 1483–1487. 6 indexed citations
14.
Cetnar, Jeremy, John M. Hampton, Tracy M. Downs, et al.. (2013). Place of Residence and Primary Treatment of Prostate Cancer: Examining Trends in Rural and Nonrural Areas in Wisconsin. Urology. 81(3). 540–547. 14 indexed citations
15.
Kabat, Geoffrey C., Mimi Kim, Juhua Luo, et al.. (2013). Menstrual and reproductive factors and exogenous hormone use and risk of transitional cell bladder cancer in postmenopausal women. European Journal of Cancer Prevention. 22(5). 409–416. 10 indexed citations
16.
Desai, Pinkal, Robert B. Wallace, Matthew L. Anderson, et al.. (2013). Prospective Analysis Of Statin Use and Risk Of Non-Hodgkin’s Lymphoma In The Women’s Health Initiative Cohort. Blood. 122(21). 4279–4279. 1 indexed citations
17.
Ewald, Jonathan A., Tracy M. Downs, Jeremy Cetnar, & William A. Ricke. (2013). Expression Microarray Meta-Analysis Identifies Genes Associated with Ras/MAPK and Related Pathways in Progression of Muscle-Invasive Bladder Transition Cell Carcinoma. PLoS ONE. 8(2). e55414–e55414. 39 indexed citations
18.
Babaian, Kara N., Matthew Truong, Jeremy Cetnar, et al.. (2012). Analysis of urological procedures in men who died from prostate cancer using a population‐based approach. British Journal of Urology. 111(3b). E65–70. 7 indexed citations
19.
Cetnar, Jeremy, George Wilding, Douglas G. McNeel, et al.. (2011). A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 31(4). 436–441. 11 indexed citations
20.
Cetnar, Jeremy, S. Bruce Malkowicz, Steven C. Palmer, Alan J. Wein, & David J. Vaughn. (2008). Pilot Trial of Adjuvant Paclitaxel Plus Estramustine in Resected High-Risk Prostate Cancer. Urology. 71(5). 942–946. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramon Andrade de Mello Breakdown of academic impact, for papers by Bo H. Chao Breakdown of academic impact, for papers by Jiuda Zhao Breakdown of academic impact, for papers by Luisa Carbognin Breakdown of academic impact, for papers by Angela Listì Breakdown of academic impact, for papers by Luciano Burattini Breakdown of academic impact, for papers by Carmen Belli Breakdown of academic impact, for papers by Erzsébet Juhász Breakdown of academic impact, for papers by Chiara Lazzari Breakdown of academic impact, for papers by Tindara Franchina
Rankless by CCL
2026